• Commenced Pivotal (Validation) clinical trial for EMVision's first commercial device, the emu™ bedside brain scanner
• First Responder Proof-of-Concept device in successful aeromedical testing, with ethics approval applications submitted
• Implemented a cost-effective strategy for continued device innovation and enhancement during the Pivotal trial

EMVision Medical Devices Ltd (ASX:EMV) has provided an update on its quarterly activities and cashflow report for the 9-month period ended 31 March 2025. The key highlights include the commencement of the Pivotal (Validation) clinical trial for the company's first commercial device, the emu™ bedside brain scanner, which is designed to support FDA De Novo clearance. The first site activated was the Royal Melbourne Hospital, and the company has also shipped devices to the University of Texas Health Science Center at Houston and the Mayo Clinic in Jacksonville, Florida. EMVision also received ethics approval for a parallel Continuous Innovation Study, which will allow the company to progress the development of additional device features and scale the training library for its diagnostic AI algorithms. The company's First Responder Proof-of-Concept device was successfully deployed via a Royal Flying Doctor Service aeromedical retrieval service, and ethics approval applications have been submitted for further usability and workflow implementation studies. EMVision also has planned attendance at several leading industry events to showcase its technology and products. The company had cash reserves of $12.58 million at the end of the quarter, with activities over the remainder of FY25 to be supported by $0.8 million of non-dilutive milestone payments under the Australian Stroke Alliance grant program.

EMVision's activities over the remainder of FY25 will be supported by $0.8 million of non-dilutive milestone payments under the Australian Stroke Alliance grant program.